Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.
The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is "final and not subject to further appeal," Liquidia said
The board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.
United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.
Price: 11.51, Change: +1.48, Percent Change: +14.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。